No Data
Johnson & Johnson, Merck Cut Jobs in China, Bloomberg Reports
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $149
CFRA Upgrades Merck to Buy
Eikon Therapeutics Announces Appointment of Michael Klobuchar as Chief Operating Officer
Merck's Keytruda subcutaneous injection version has reached the main endpoint of phase 3 trials.
Merck stated that in a key phase 3 trial, the subcutaneous version of the anti-PD1 drug achieved its primary endpoint, with performance comparable to the FDA-approved intravenous version, making it a first-line option for lung cancer.
Merck & Co To Go Ex-Dividend On December 16th, 2024 With 0.81 USD Dividend Per Share
loading...
No Data
No Data
